{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:11:54Z","timestamp":1760616714605,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["HZC115151","NCT01551758"],"award-info":[{"award-number":["HZC115151","NCT01551758"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.rmed.2018.12.016","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T17:29:05Z","timestamp":1547141345000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Benefit and safety of fluticasone furoate\/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups"],"prefix":"10.1016","volume":"147","author":[{"given":"Nawar Diar","family":"Bakerly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Leather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"New","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Boucot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"Global Strategy for the diagnosis, management, and prevention of chronic obstructive lung disease","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","key":"10.1016\/j.rmed.2018.12.016_bib1"},{"issue":"2","key":"10.1016\/j.rmed.2018.12.016_bib2","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J. Glob. Health"},{"year":"2018","series-title":"Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management, NICE Guideline NG115","author":"National Institute for Health and Care Excellence","key":"10.1016\/j.rmed.2018.12.016_bib3"},{"issue":"4","key":"10.1016\/j.rmed.2018.12.016_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152618","article-title":"Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries","volume":"11","author":"Foo","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.rmed.2018.12.016_bib5","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib6","first-page":"166","article-title":"Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns","volume":"1","author":"Agust\u00ed","year":"2014","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2018.12.016_bib7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2018.12.016_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12931-016-0433-5","article-title":"Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy","volume":"17","author":"Halpin","year":"2016","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.016_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.rmed.2004.03.026","article-title":"How representative are clinical study patients with asthma or COPD for a larger \u201creal life\u201d population of patients with obstructive lung disease?","volume":"99","author":"Herland","year":"2005","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000355082","article-title":"What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?","volume":"87","author":"Scichilone","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2018.12.016_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.rmed.2006.10.011","article-title":"External validity of randomized controlled trials in COPD","volume":"101","author":"Travers","year":"2007","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/thoraxjnl-2013-203724","article-title":"Limited generalisability of UPLIFT findings to clinical practice","volume":"68","author":"Walker","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.12.016_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01531-2017","article-title":"Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability","volume":"51","author":"Woodcock","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2018.12.016_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1740774512450097","article-title":"The role of pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research","volume":"9","author":"Chalkidou","year":"2012","journal-title":"Clin. Trials"},{"issue":"5","key":"10.1016\/j.rmed.2018.12.016_bib16","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A primer on effectiveness and efficacy trials","volume":"2","author":"Singal","year":"2014","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.rmed.2018.12.016_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-10-37","article-title":"Making trials matter: pragmatic and explanatory trials and the problem of applicability","volume":"10","author":"Treweek","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.rmed.2018.12.016_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12931-015-0267-6","article-title":"The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease","volume":"16","author":"Bakerly","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2018.12.016_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/thoraxjnl-2014-205259","article-title":"Obtaining real-world evidence: the Salford lung study","volume":"69","author":"New","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2018.12.016_bib20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/15412555.2013.776920","article-title":"COPD assessment test \u2014 rationale, development, validation and performance","volume":"10","author":"Jones","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2018.12.016_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2018.12.016_bib23","first-page":"CD010115","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"3","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmed.2018.12.016_bib24","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). EMA\/330021\/2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Inhaled_corticosteroids_Article_31\/European_Commission_final_decision\/WC500210491.pdf, Accessed 15 May 2017."},{"key":"10.1016\/j.rmed.2018.12.016_bib25","unstructured":"European Medicines Agency. EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease. EMA\/488280\/2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Inhaled_corticosteroids_Article_31\/European_Commission_final_decision\/WC500210489.pdf, Accessed 7 March 2018."},{"issue":"1","key":"10.1016\/j.rmed.2018.12.016_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann. Am. Thorac. Soc."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:43:08Z","timestamp":1760614988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119300083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"alternative-id":["S0954611119300083"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.12.016","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit and safety of fluticasone furoate\/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}